08 November 2017
: Case report
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient’s Perspective
Unusual clinical course, Challenging differential diagnosis
Richard C. Josiassen1ADE*, Dawn M. Filmyer2ABDE, Jack Gillean34BC, Syed Sikandar Shah45BC, Tyler E. Dietterich2F, Rita A. Shaughnessy24ABDEDOI: 10.12659/AJCR.906454
Am J Case Rep 2017; 18:1185-1189
Abstract
BACKGROUND: Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD.
CASE REPORT: We describe the case of a 49-year-old African-American woman who was diagnosed with bipolar disorder at the age of 34 and treated with lithium carbonate (900 mg daily) and citalopram (10 mg daily). She also received low doses of second-generation antipsychotics for weeks at a time, but these were always discontinued due to severe sedation. Over a decade later, at the age of 45, she experienced rapid onset of severe TD symptoms. She enrolled in a phase III double-blind clinical trial and received valbenazine 80 mg, with encouraging results.
CONCLUSIONS: Once-daily dosing of valbenazine (80 mg) was effective and safe over a long period, even in this atypical case of severe and rapid-onset TD.
Keywords: Movement Disorders, Vesicular Monoamine Transport Proteins
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946560
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946727
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946839
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946674
Most Viewed Current Articles
21 Jun 2024 : Case report
96,182
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,159
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
31,026
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,365
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030